Literature DB >> 21761212

[Successful treatment of Darier disease with oral alitretinoin].

S E Barnstedt1.   

Abstract

A 18-year-old man with severe Darier disease was treated with alitretinoin 30 mg daily. In addition he used topical keratolytic agents. The duration of treatment was 52 weeks. First significant improvement was noted within one week after starting treatment. Itchiness and erythema, particularly on the head and in the chest area, decreased spontaneously after starting the treatment. From week 4 on a remarkable reduction in scaling, fissures and hyperkeratosis was observed. After 52 weeks the patient was clear of disease, except for residual symptoms on his chest. Treatment was well tolerated without any side effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21761212     DOI: 10.1007/s00105-011-2207-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  7 in total

Review 1.  Management of Darier's disease.

Authors:  S Burge
Journal:  Clin Exp Dermatol       Date:  1999-03       Impact factor: 3.470

2.  Isotretinoin treatment of Darier's disease.

Authors:  C H Dicken; E A Bauer; P G Hazen; G G Krueger; J G Marks; J S McGuire; L A Schachner
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

3.  [Hyperkeratotic variant of Darier's disease. Successful oral treatment using an aromatic retinoid (Ro 10-9395)].

Authors:  H Hönigsmann; P Fritsch; E Jaschke
Journal:  Hautarzt       Date:  1978-11       Impact factor: 0.751

4.  A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease.

Authors:  J Christophersen; J M Geiger; P Danneskiold-Samsoe; K Kragballe; F G Larsen; G Laurberg; J Serup; K Thomsen
Journal:  Acta Derm Venereol       Date:  1992       Impact factor: 4.437

5.  Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.

Authors:  T Ruzicka; C W Lynde; G B E Jemec; T Diepgen; J Berth-Jones; P J Coenraads; A Kaszuba; R Bissonnette; E Varjonen; P Holló; F Cambazard; M Lahfa; P Elsner; F Nyberg; A Svensson; T C Brown; M Harsch; J Maares
Journal:  Br J Dermatol       Date:  2008-02-21       Impact factor: 9.302

6.  Oral treatment of keratosis follicularis with a new aromatic retinoid.

Authors:  C E Orfanos; M Kurka; V Strunk
Journal:  Arch Dermatol       Date:  1978-08

Review 7.  Alitretinoin: a comprehensive review.

Authors:  Caleb Cheng; Jason Michaels; Noah Scheinfeld
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

  7 in total
  5 in total

Review 1.  [Retinoids in dermatopharmacology].

Authors:  P M Amann; H F Merk; J M Baron
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

Review 2.  [Off-label use of alitretinoin].

Authors:  K Fritz; G S Tiplica; C Salavastru; M Onder
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

3.  [Darier disease].

Authors:  A Klausegger; M Laimer; J W Bauer
Journal:  Hautarzt       Date:  2013-01       Impact factor: 0.751

4.  A Case Report of Hailey-Hailey Disease Treated with Alitretinoin.

Authors:  A Young Park; Ho Jung Lee; Euy Hyun Chung; Jung Eun Kim; Jong Suk Lee; Sang Hoon Lee; Sung Yul Lee
Journal:  Ann Dermatol       Date:  2019-07-01       Impact factor: 1.444

5.  Alitretinoin in Dermatology-An Update.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.